Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
BCL-XL is an actionable target for treatment of malignant pleural mesothelioma.
Arulananda S, O'Brien M, Evangelista M, Harris TJ, Steinohrt NS, Jenkins LJ, Walkiewicz M, O'Donoghue RJJ, Poh AR, Thapa B, Williams DS, Leong T, Mariadason JM, Li X, Cebon J, Lee EF, John T, Fairlie WD. Arulananda S, et al. Among authors: walkiewicz m. Cell Death Discov. 2020 Oct 31;6(1):114. doi: 10.1038/s41420-020-00348-1. Cell Death Discov. 2020. PMID: 33298868 Free PMC article.
A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma.
Arulananda S, O'Brien M, Evangelista M, Jenkins LJ, Poh AR, Walkiewicz M, Leong T, Mariadason JM, Cebon J, Balachander SB, Cidado JR, Lee EF, John T, Fairlie WD. Arulananda S, et al. Among authors: walkiewicz m. Cell Death Discov. 2021 May 28;7(1):122. doi: 10.1038/s41420-021-00505-0. Cell Death Discov. 2021. PMID: 34050131 Free PMC article.
Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma.
Arulananda S, O'Brien M, Evangelista M, Harris TJ, Steinohrt NS, Jenkins LJ, Walkiewicz M, O'Donoghue RJJ, Poh AR, Thapa B, Williams DS, Leong T, Mariadason JM, Li X, Cebon J, Lee EF, John T, Fairlie WD. Arulananda S, et al. Among authors: walkiewicz m. Cell Death Discov. 2021 Jun 15;7(1):146. doi: 10.1038/s41420-020-00388-7. Cell Death Discov. 2021. PMID: 34131107 Free PMC article. No abstract available.
Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.
Russell PA, Barnett SA, Walkiewicz M, Wainer Z, Conron M, Wright GM, Gooi J, Knight S, Wynne R, Liew D, John T. Russell PA, et al. Among authors: walkiewicz m. J Thorac Oncol. 2013 Apr;8(4):461-8. doi: 10.1097/JTO.0b013e3182828fb8. J Thorac Oncol. 2013. PMID: 23486266 Free article.
120 results